Recruiting Macular Degeneration Studies in Ann Arbor
About Macular Degeneration Clinical Trials in Ann Arbor
Age-related macular degeneration (AMD) is the leading cause of severe vision loss in Americans over 50, affecting over 11 million people. Wet (neovascular) AMD involves abnormal blood vessel growth under the retina, while dry AMD involves gradual thinning of the macula and accumulation of drusen deposits. Current treatment for wet AMD relies on anti-VEGF injections (ranibizumab, aflibercept, faricimab), with newer high-dose and extended-interval formulations reducing treatment burden. For geographic atrophy (advanced dry AMD), complement inhibitors like pegcetacoplan (Syfovre) represent the first approved treatments. Clinical trials are testing gene therapies, implantable drug delivery systems, stem cell therapies, and novel targets beyond VEGF for both wet and dry AMD.
There are currently 1 macular degeneration clinical trials recruiting participants in Ann Arbor, MI. These studies are seeking a combined 18 participants. Research is being sponsored by Luxa Biotechnology, LLC. Clinical trial participation is free and participants receive study-related medical care at no cost.
Macular Degeneration Clinical Trials in Ann Arbor — FAQ
Are there macular degeneration clinical trials in Ann Arbor?
Yes, there are 1 macular degeneration clinical trials currently recruiting in Ann Arbor, MI. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Ann Arbor?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Ann Arbor research site will contact you about next steps.
Are clinical trials in Ann Arbor free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Ann Arbor studies also compensate for your time and travel.
What macular degeneration treatments are being tested?
The 1 active trials in Ann Arbor are testing new therapies including novel drugs, biologics, and treatment approaches for macular degeneration.
Data updated March 2, 2026 from ClinicalTrials.gov